Page 3 - Glenmark Pharmaceuticals

Glenmark, Laurus Lab: Will Trump's 200% tariff threat derail pharma stocks?

Donald Trump threatens of a potential 200% tariff on pharma imports; can this derail the rally in pharma shares, which have gained up to 50% in 3 months. Here's what the technical charts suggest.

Glenmark Pharmaceuticals shares up 3% on launching cancer drug Tevimbra

Glenmark Pharmaceuticals share price gained in trade after the company announced the launch of Tevimbra (tislelizumab) in India, following approval by the Central Drugs Standard Control Organisation.

Glenmark Pharma launches lung cancer treatment drug Tevimbra in India

Glenmark Pharmaceuticals on Tuesday said it has launched the lung cancer treatment drug Tevimbra in India, following the approval by the Central Drugs Standard Control Organisation. Tevimbra is developed by BeiGene (now BeOne Medicines), a global oncology leader. This launch marks Glenmark's first foray into immune-oncology in India and is a major milestone in expanding its innovative oncology portfolio, the company said in a regulatory filing. "At a time when the cancer burden is rising sharply, we are proud to enable oncologists and patients to access Tevimbra, a therapy with proven efficacy and safety outcomes, strong science, and meaningful impact," Glenmark Pharmaceuticals President and Business Head India Formulations Alok Malik said. Immuno-oncology offers a promising future for the treatment of various types of advanced cancers, which are difficult to treat, he said, adding that "Our foray in this area marks a significant inflection point in our journey to build a world-clas

Glenmark Pharma rises 2% as company to launch blood cancer treatment drug

Glenmark Pharma shares gained 2 per cent in trade as company announced the upcoming launch of zanubrutinib, under the brand name Brukinsa in India

Glenmark set to launch blood cancer treatment drug Brukinsa in India

Glenmark will introduce Brukinsa, a BTK inhibitor developed by BeOne Medicines, in India after DCGI approval to treat five B-cell blood cancers with proven safety and efficacy

Stocks to buy today, June 5: Glenmark Pharma, M&M among analyst top picks

Stocks to buy today, June 5: Analyst at Religare Broking has recommended buying Glenmark Pharma, M&M and one more stock with upside potential

Glenmark's cancer drug shows strong results in early trial for Myeloma

In the dose-escalation stage of the trial, 35 patients were treated, most of whom had received a median of six prior therapies

Stock Market Close Highlights: Sensex jumps 455 points, Nifty at 25,001; all sectors settle in green

Sensex Today | Stock Market Close Highlights Monday, May 26, 2025: Among the Sensex constituents, 22 out of 30 stocks ended higher, with gains led by M&M, HCL Tech, Tata Motors, and Nestle India

Stocks to Watch, May 26: JSW Steel, NTPC, Glenmark Pharma, ONGC, Info Edge

Stocks to Watch on Monday: JSW Steel, NTPC, Glenmark Pharma, ONGC, Transrail Lighting, Info Edge and Lloyds Engineering Works are among the stocks to watch today, May 26, 2025

Nifty Pharma drops 2% after Trump reveals plans to lower US drug cost

The US President has predicted that pharmaceutical prices could drop 30 per cent to 80 per cent in America

5 stocks that look good on charts amid market volatility; check list here

Shares of Glenmark, Chambal Fertilisers, Blue Dart, Max Healthcare and CCL Products may trade with a positive bias in the near-term as these stocks are favourably placed on the technical charts.

Analyst suggests buying CDSL, Hero Motocorp, Glenmark Pharma: Check TP

The stock has broken above its 200 DEMA with rising volumes in the last few sessions. The RSI indicator is rising to support the positive momentum

Glenmark, Sun Pharma, Zydus recall products in US over manufacturing issues

Drug makers Glenmark, Sun Pharma and Zydus are recalling products in the US for manufacturing issues, the US Food and Drug Administration (USFDA) said in its latest Enforcement Report. As per the US health regulator, Mumbai-based Glenmark is recalling over 25 products in the US market due to Current Good Manufacturing Practice (CGMP) deviations. New Jersey-based Glenmark Pharmaceuticals Inc is recalling affected lots of medications like Propafenone Hydrochloride extended-release capsules and Solifenacin Succinate Tablets in America, the USFDA said. It is also recalling products like Voriconazole Tablets, Lacosamide Tablets, Frovatriptan Succinate Tablets and Rufinamide Tablets. The company initiated the Class II recall on March 13 this year. As per the USFDA, a Class-II recall is initiated when the use of, or exposure to, a violative product may lead to temporary or medically reversible health consequences, or when the likelihood of serious adverse health outcomes is minimal. A .

Glenmark Pharma share rises 2% on securing USFDA nod; key details here

Glenmark Pharma's stock rose after it said Glenmark Pharmaceuticals Inc., USA, has received final approval from the USFDA for its Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%

Glenmark launches Empagliflozin for diabetes in India under Glempa brand

Glenmark Pharmaceuticals on Wednesday said it has launched a medication for glycemic control and weight-loss for diabetes patients. The Mumbai-based drug firm has launched Empagliflozin, a widely recognised SGLT2 inhibitor, under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)'?Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg). The medications are designed to improve glycemic control in adults with type 2 diabetes mellitus while also reducing cardiovascular outcomes in patients with cardiovascular risk. Studies have demonstrated several benefits of Empagliflozin, including effectively improving glycemic control, supporting weight-loss, and reducing cardiovascular-renal risks in patients with type 2 diabetes mellitus. Empagliflozin has also demonstrated benefits in heart failure patients by lowering the cardiovascular death or hospitalisation. "The launch of Glempa range ..

Stocks to watch, Mar 3: Auto stocks, Coal India, Hindustan Zinc, ACME Solar

Stock market today: Glenmark Pharma is recalling close to 15 lakh bottles of a generic medication used in treating attention deficit hyperactivity disorder in the US market, as reported by the US FDA

Glenmark recalls 1.5 million bottles of ADHD medication in US: USFDA

Glenmark Pharmaceuticals is recalling close to 15 lakh bottles of a generic medication used in the treatment of attention deficit hyperactivity disorder in the US market, according to the US health regulator. Glenmark Pharmaceuticals Inc, USA, a subsidiary of the Mumbai-based drug maker, is recalling around 14.76 lakh bottles of Atomoxetine Capsules in multiple strengths. The company is recalling the affected lot due to "CGMP Deviations", the US Food and Drug Administration (USFDA) said in its latest Enforcement Report. The recall is due to "presence of N-Nitroso Atomoxetine impurity above the FDA recommended limit," it added. New Jersey-based Glenmark Pharmaceuticals Inc, USA is recalling the made-in-India product in strengths ranging from 10 mg to 100 mg, USFDA stated. The company initiated the Class II recall on January 29 this year. As per the USFDA, a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medic

Zydus Lifesciences, Granules, Glenmark: Nifty Pharma up despite weak market

Nifty Pharma among others has gained 0.8 per cent in trade, logging an intra-day high at 20,550.6

Glenmark, FDC recall products from US market on manufacturing issues: USFDA

Drug firms Glenmark Pharmaceuticals and FDC Ltd are recalling products in the US market due to manufacturing issues, according to the US Food and Drug Administration (USFDA). In its latest Enforcement Report, the US health regulator said a US-based subsidiary of Mumbai-headquartered Glenmark Pharmaceuticals is recalling a certain number of a generic hypertension medication in the US market. New Jersey-based Glenmark Pharmaceuticals Inc, USA is recalling Carvediol tablets in strengths of 25 mg and 12.5 mg in the US, the US health regulator stated. The company is recalling the product as "N-Nitroso Carvedilol I impurity (NNCI-I) were found to be failing per current FDA recommended limit". The company initiated the Class II recall on January 22 this year. USFDA said FDC Ltd is recalling 1,18,104 bottles of a medication for the treatment of glaucoma. The drug firm is recalling the affected lot of Timolol Maleate ophthalmic solution USP produced at its Aurangabad-based plant, it added

Glenmark Pharma Q3 results: Net profit down at Rs 348 cr on weak US sales

The company reported a loss of Rs 351 crore in the comparable quarter last year, hurt by sluggish sales in India and charges related to a legal case settlement in the United States